Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2021-11-25
Target enrollment:
Participant gender:
Summary
This pilot study evaluates the use of high-intensity focused ultrasound (HIFU) combined with
pembrolizumab in patients with metastatic breast cancer. One-half of participants will be
randomized to receive the first dose of pembrolizumab after HIFU and one-half of participants
will be randomized to receive their first dose of pembrolizumab before HIFU.